Saudi ArabiaTuberculosis profile
Population  2014 31 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.65 (0.21–1.4) 2.1 (0.67–4.4)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 4.8 (2.1–8.8) 16 (6.6–28)
Incidence  (includes HIV+TB) 3.9 (3.4–4.4) 12 (11–14)
Incidence (HIV+TB only) 0.13 (0.11–0.16) 0.43 (0.36–0.5)
         
Case detection, all forms (%) 84 (75–96)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.8 (1.4–2.4) 16 (12–21)
MDR-TB cases among notified pulmonary
TB cases
42 (33–56) 29 (22–38)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 942   93
Pulmonary, clinically diagnosed 412   4
Extrapulmonary 789   8
       
Total new and relapse 3 248    
Previously treated, excluding relapses 88    
Total cases notified 3 336    
Among 3 248 new and relapse cases:
103 (3%) cases aged under 15 years; male:female ratio: 2.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 091 (56%) 82 (42%) 1 173
Laboratory-confirmed RR-/MDR-TB cases     67
Patients started on MDR-TB treatment ***     51
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 781 (53)
HIV-positive TB patients 63 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (56) 3 435
Previously treated cases, excluding relapse, registered in 2013 (39) 127
HIV-positive TB cases, all types, registered in 2013 (17) 77
RR-/MDR-TB cases started on second-line treatment in 2012 (25) 20
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-29 Data: www.who.int/tb/data